Bioinformatics company providing evidence-based, clinically beneficial molecular diagnostic tests and pathology services.
Location: United States, New Jersey, Parsippany-Troy Hills
Total raised: $20M
Investors 2
| Date | Name | Website |
| - | BroadOak C... | broadoak.c... |
| - | 1315 Capit... | 1315capita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2020 | - | $20M | 1315 Capit... |
Mentions in press and media 6
| Date | Title | Description |
| 07.03.2024 | Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results | - |
| 13.01.2022 | Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering | PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. U... |
| 12.01.2022 | Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering | PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million. U... |
| 04.01.2022 | Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering | Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it has ... |
| 03.01.2022 | Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering | Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it has ... |
| 13.01.2020 | Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital a... | - |